Adalimumab is a human monoclonal antibody which targets tumor necrosis factor 
(TNF)-alpha. It is produced by recombinant DNA technology, using a mammalian 
cell expression system and is widely-known to treat a number of immune-mediated 
conditions, including psoriasis. There has been a growing concern regarding the 
possible association between TNF-alpha inhibitors and malignancy. In this case 
report, we describe the case of a 20-year-old woman, known to have been 
suffering from chronic plaque psoriasis for 12 years, and who developed 
Hodgkin's lymphoma within five weeks of beginning adalimumab treatment.